IDeate-Lung02

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jan 12, 2024 → Oct 24, 2026

Cited window

Mar 27, 2024 → Oct 8, 2026

Retrieved

Oct 29, 2026

Title

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)

Registry

NCT06203210

Study IDs

DS7300-188 · 2023-509628-16-00 (EU CT) · 2031230631 (jRCT)

Sponsor

Daiichi Sankyo

Collaborators

Merck Sharp & Dohme LLC

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

540 estimated

Registered

2024-01-12

Start

2024-05-21 actual

Primary completion

2028-01-30 estimated

Primary endpoint

Overall Survival (OS)

Interventions

4 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on reduced monitoring requirements and community feasibility of an alternative treatment for relapsed small cell lung cancer.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –86 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are not representative of all HCP discussion. Unnamed references, differently rendered trial names and incompletely evaluated passages may leave relevant views absent.
• –The material mixes physician commentary with organizational, company-relay and public-account statements. Uncertain clinical roles and unnamed authors limit conclusions about clinician consensus.
• –Audio/video versions of one episode, duplicated posts and reposts should not be counted as independent agreement.
• –Earlier response, CNS and safety observations belong to IDeate-PanTumor01 or IDeate-Lung01, not to randomized IDeate-Lung02 efficacy results.
• –Reports of the phase 3 interruption do not provide the fatal-ILD count or incidence. Global recruitment interruption, a US partial hold and later reported continuation have different scopes and dates.
• –FDA's specific reason for finding the accelerated-approval evidence insufficient remains unresolved in these accounts. Suggested explanations involving available therapy, response durability, safety or design remain attributed interpretations.
• –The published design article and registry-based discussion differ on primary endpoint status. The sources do not establish the complete amendment history or whether an earlier filing-supporting analysis will occur.
• –Cross-trial comparisons differ by treatment line, geography, eligibility and time. They do not establish comparative efficacy, safety or absence of benefit.
• –A published study-design article is available, but no separate protocol document was listed with the registry material. Product-label coverage is incomplete, including no exact I-DXd or amrubicin label, so regulatory and treatment-availability commentary is not a comprehensive label assessment.
• –The rebiopsy statement is truncated, and the liquid-biopsy and subtype discussions do not provide a validated I-DXd treatment-selection rule.

How reports are built and checked: Methods.

Last checked for new commentary Oct 30, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "IDeate-Lung02" (NCT06203210), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "ideate-lung02-06203210". If you cannot make requests, read https://www.erudio.com/reports/ideate-lung02-nct06203210.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06203210", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06203210 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/ideate-lung02-nct06203210.json
curl https://www.erudio.com/reports/ideate-lung02-nct06203210.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "ideate-lung02-06203210" })